PeptideUniv

BPC-157 vs TB-500: Comparison and Research Overview

BPC-157 and TB-500 are often grouped together in “tissue repair” conversations, but they are different compounds with different origins and different proposed mechanisms.

This page compares what each compound is, what kinds of claims are commonly made, and what to look for in primary research. Educational use only; not medical advice.

What they are (and what they are not)

BPC-157 is a synthetic (lab-made) peptide fragment made up of 15 amino acids; BPC stands for “Body Protection Compound,” and “157” is the research identifier for this specific fragment.

TB-500 is a peptide derived from thymosin beta-4 and is also discussed in preclinical “repair” contexts.

Neither compound has a standard, widely accepted clinical dosing framework. Online summaries often go beyond what the primary literature supports.

Mechanism comparison (high-level)

You will see both compounds described as supporting “tissue repair,” but the proposed mechanisms are not the same and are not always stated carefully.

Practical takeaway: treat mechanism statements as hypotheses unless they are backed by primary studies.

Evidence landscape (what to trust)

A lot of content online mixes animal studies, cell studies, and anecdote. That makes direct comparisons unreliable.

Measurement and protocol design notes

Reconstitution math is the same for any peptide: vial amount ÷ diluent volume gives concentration (mg/mL). Then you convert a target dose to mL and U-100 units.

This page does not give dosing instructions. Use primary research and protocol context for study design decisions.

Summary

For educational and research purposes only. Not medical advice. Consult a licensed healthcare professional for personal guidance.